SCSK Corporation
SCSK Corporation (9719.T) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for SCSK Corporation (9719.T), covering cash flow, earnings, and balance sheets.
SCSK Corporation (9719.T) Income Statement & Financial Overview
Access detailed annual and quarterly income data for SCSK Corporation 9719.T financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $211.22B | $133.32B | $128.98B | $122.54B |
| Cost of Revenue | $154.31B | $96.62B | $94.45B | $91.21B |
| Gross Profit | $56.91B | $36.70B | $34.53B | $31.34B |
| Gross Profit Ratio | $0.27 | $0.28 | $0.27 | $0.26 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $32.38B | $20.75B | $19.30B | $19.09B |
| Operating Expenses | $32.38B | $20.75B | $19.30B | $19.09B |
| Total Costs & Expenses | $186.69B | $117.37B | $113.75B | $109.18B |
| Interest Income | $309.00M | $154.00M | $144.00M | $142.00M |
| Interest Expense | $2.04B | $243.00M | $207.00M | $242.00M |
| Depreciation & Amortization | $8.33B | $5.52B | $5.54B | $5.48B |
| EBITDA | $31.86B | $21.45B | $19.73B | $18.53B |
| EBITDA Ratio | $0.15 | $0.16 | $0.15 | $0.15 |
| Operating Income | $24.54B | $15.95B | $15.23B | $12.24B |
| Operating Income Ratio | $0.12 | $0.12 | $0.12 | $0.10 |
| Other Income/Expenses (Net) | -$3.04B | $19.00M | -$1.25B | $1.02B |
| Income Before Tax | $21.49B | $15.96B | $13.98B | $13.27B |
| Income Before Tax Ratio | $0.10 | $0.12 | $0.11 | $0.11 |
| Income Tax Expense | $5.50B | $5.28B | $4.26B | $4.006B |
| Net Income | $15.24B | $10.56B | $10.02B | $9.22B |
| Net Income Ratio | $0.07 | $0.08 | $0.08 | $0.08 |
| EPS | $48.75 | $33.79 | $32.04 | $29.51 |
| Diluted EPS | $48.75 | $33.79 | $32.04 | $29.51 |
| Weighted Avg Shares Outstanding | $312.54M | $312.54M | $312.54M | $312.45M |
| Weighted Avg Shares Outstanding (Diluted) | $312.54M | $312.54M | $312.54M | $312.45M |
Over the last four quarters, SCSK Corporation's revenue moved from $122.54B in Q1 2024 to $211.22B in Q4 2024. Operating income in Q4 2024 was $24.54B, with a strong operating margin of 12%. Despite fluctuations in R&D and SG&A expenses, EBITDA for SCSK Corporation remained robust at $31.86B, reflecting operational efficiency. Net income rose to $15.24B, with an EPS of $48.75. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan